Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, specifically targeting the NBD1 domain. The company reports significant operating losses and anticipates needing substantial additional funding to advance its lead dual combination candidate, SION-451 + SION-2222, through clinical trials.
Sionna Therapeutics reported Q3 2026 financial results and announced plans to initiate the AscenSION CF Phase 2 proof-of-concept trial for its SION-451 and SION-2222 dual combination in Q1 2027. The company ended the quarter with $249.8 million in cash, which is expected to fund operations into the second half of 2029.
Term
Q3 2026
“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination. We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination’s favorable Phase 1 results, support advancing the dual combination into the next phase of development. With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF.”
Mike Cloonan, President and Chief Executive Officer
Sionna Therapeutics Director Ra Capital Management L.P. Sells $21.8M of Stock
Ra Capital Management L.P., Director, sold 3,448,811 shares of Sionna Therapeutics, Inc. at $6.32 to $7.46 a share (average $6.33) in 2 transactions, worth $21.8M in total on Sep 17, 2026. Shares held after the trade: 3,448,812 (-1.0%).